Abstract
High-risk neuroblastoma remains one of the most challenging pediatric cancers to treat, with survival rates below 50% and an even poorer prognosis for relapsed patients. Current treatment strategies heavily rely on chemotherapy, often causing severe side effects by targeting both cancerous and healthy cells. Precision medicine, which tailors therapies to
... read more